USP20 governs tyrosine kinase inhibitors resistance through ferroptosis evasion by targeting GPX4 in cancers
Tyrosine kinase inhibitors (TKIs) including sunitinib and sorafenib remain first-line therapies for advanced renal cell carcinoma (RCC) and lung cancer (LC), but their efficacy is limited by acquired resistance. By characterizing metabolic adaptations in TKI-resistant tumors, we identify ubiquitin-s...
Guardat en:
| Autors principals: | , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier
2026-05-01
|
| Col·lecció: | Redox Biology |
| Matèries: | |
| Accés en línia: | http://www.sciencedirect.com/science/article/pii/S2213231726000844 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|